Groundbreaking Cambridge research indicates immunosuppression may help treat Parkinson’s
A pioneering trial, led from Cambridge Biomedical Research Centre, has shown that immunosuppressing medicines could provide the key to treatment of Parkinson's disease, according to results presented this weekend at the world's most prestigious neurodegeneration conference AD/PD
The AZA/PD trial which was carried out at the NIHR Cambridge Clinical Research Facility is the first show that broadly suppressing the immune system could have a beneficial impact in Parkinson's disease.
Participants on the treatment reported an overall improvement in movement-related symptoms. This means they found it easier to perform tasks such as moving around, writing, washing and dressing.
These improvements were greater in female participants compared to males.
Additionally, patients with faster-progressing Parkinson's disease showed signs of improved memory and thinking skills. Importantly, the trial did not reveal significant safety concerns around using immunosuppression treatment in Parkinson's disease. This will enable larger research studies of immune therapies for PD in the future.
For full article visit: CUH News
Latest from CCTU
Groundbreaking Cambridge research indicates immunosuppression may help treat Parkinson’s
A pioneering trial, led from Cambridge Biomedical Research Centre, has shown that…
AI power improves cataract test tool for babies
A device invented by an Addenbrooke's eye surgeon to detect cataract in babies is set to be further improved - thanks to artificial intelligence and a team…
Research sets global standard for Crohn’s treatment
Trial results published by Cambridge researchers earlier this year and involving patients at Addenbrooke’s Hospital are helping to set new global standards…
